Aescin

Pharmacodynamics and active components

The basis of Aescinum (often available in pharmacies under the brand name Venitan) is a phytoextract derived from horse chestnut seeds. Its pharmacological activity is due to the presence of specific saponins and flavonoids. Interestingly, these flavonoids show structural similarity to rutosides.

The action of aescin is complex. First of all, it acts as a classic venotonic: increases venous tone and decreases capillary permeability. By stabilizing the vascular wall, it sharply reduces fluid exudation into the intercellular space. This exact mechanism provides a potent anti-edematous effect. In addition, the drug effectively improves tissue microcirculation, relieves local inflammation, and has a mild analgesic effect, making it indispensable in acute vascular pathologies and injuries.

Indications for clinical practice

Due to its wide range of effects (from anti-inflammatory to venotonic), aescin is actively used by surgeons, phlebologists, and traumatologists. The main pool of indications is associated with impaired venous outflow and traumatic injuries.

The drug is prescribed for the following conditions:

• Chronic venous insufficiency and clinically pronounced varicose vein disease.
• Acute manifestations of proctological diseases, particularly hemorrhoids strictly in the exacerbation stage.
• Inflammatory venous disorders: superficial thrombophlebitis, as well as post-thrombophlebitis syndrome.
• Traumatological profile: soft tissue contusions, ligament sprains, extensive hematomas.
• Pronounced post-traumatic or postoperative edema.

Contraindications and risk groups

Despite the fact that aescin is an herbal medicine, its safety profile requires strict adherence to instructions. The drug is strictly prohibited in the presence of individual hypersensitivity to horse chestnut extract or excipients.

Absolute contraindications also include:

• Severe renal failure (mandatory monitoring of renal function is required before prescribing).
• First trimester of pregnancy (due to the risk of negative impact in early gestation).
• Childhood and adolescence under 18 years of age.

The physician must exercise extreme caution when treating patients with concomitant gastrointestinal diseases and hepatic impairment. The drug is also used with caution during lactation (breastfeeding).

Side effect profile

Clinical observations show that adverse reactions during aescin therapy develop quite rarely. If side effects do occur, they are usually mild, transient, and do not require immediate discontinuation of therapy.

The main groups of adverse events include:

• Gastrointestinal tract: patients may report nausea, episodes of diarrhea, dyspeptic symptoms, and moderate abdominal pain.
• Allergic reactions: cutaneous manifestations in the form of pruritus, erythematous rash, or classic urticaria.
• Central nervous system: complaints of dizziness and headache are occasionally recorded.

Class and exam questions

What else to study on this topic

• Troxerutin: mechanism of action of a semisynthetic rutin derivative
• Use of troxerutin in diabetic retinopathy
• Endotelon: red grape seed extract in the treatment of venous insufficiency
• Effect of venotonics on lymphatic vessels (using Endotelon as an example)
• Comparative profile of side effects of herbal and semisynthetic venotonics

Other topics in the "Angioprotectors" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.